AMRX Amneal Pharmaceuticals Inc

Price (delayed)

$4.97

Market cap

$1.49B

P/E Ratio

10.8

Dividend/share

N/A

EPS

$0.46

Enterprise value

$4.16B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

The company's net income has surged by 132% QoQ and by 118% YoY
AMRX's EPS has soared by 130% since the previous quarter and by 118% year-on-year
AMRX's debt is up by 7% year-on-year

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
299.75M
Market cap
$1.49B
Enterprise value
$4.16B
Valuations
Price to earnings (P/E)
10.8
Price to book (P/B)
4.95
Price to sales (P/S)
0.39
EV/EBIT
36.46
EV/EBITDA
12.11
EV/Sales
2.22
Earnings
Revenue
$1.88B
EBIT
$114.21M
EBITDA
$344.03M
Free cash flow
$186.5M
Per share
EPS
$0.46
Free cash flow per share
$1.26
Book value per share
$1
Revenue per share
$12.74
TBVPS
$14.68
Balance sheet
Total assets
$4.04B
Total liabilities
$3.69B
Debt
$2.96B
Equity
$301.04M
Working capital
$875.83M
Liquidity
Debt to equity
9.83
Current ratio
2.31
Quick ratio
1.48
Net debt/EBITDA
7.78
Margins
EBITDA margin
18.3%
Gross margin
30.4%
Net margin
3.3%
Operating margin
2.5%
Efficiency
Return on assets
1.5%
Return on equity
21.4%
Return on invested capital
2.8%
Return on capital employed
3.4%
Return on sales
6.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
2.26%
1 week
2.9%
1 month
15.58%
1 year
-3.12%
YTD
8.75%
QTD
8.75%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$1.88B
Gross profit
$571.56M
Operating income
$47.84M
Net income
$61.97M
Gross margin
30.4%
Net margin
3.3%
The company's operating income has surged by 172% QoQ and by 124% YoY
The operating margin has surged by 166% since the previous quarter and by 121% year-on-year
The company's net income has surged by 132% QoQ and by 118% YoY
AMRX's net margin has surged by 129% since the previous quarter and by 117% year-on-year

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
10.8
P/B
4.95
P/S
0.39
EV/EBIT
36.46
EV/EBITDA
12.11
EV/Sales
2.22
AMRX's EPS has soared by 130% since the previous quarter and by 118% year-on-year
Amneal Pharmaceuticals's equity has increased by 38% YoY
The price to book (P/B) is 10% higher than the last 4 quarters average of 4.5
AMRX's revenue is up by 9% year-on-year and by 8% since the previous quarter
The price to sales (P/S) is 2.5% lower than the last 4 quarters average of 0.4

Efficiency

How efficient is Amneal Pharmaceuticals business performance
The company's return on assets has surged by 131% QoQ and by 119% YoY
Amneal Pharmaceuticals's return on equity has surged by 130% QoQ and by 126% YoY
AMRX's ROS has dropped by 59% since the previous quarter and by 51% year-on-year
AMRX's ROIC has plunged by 56% from the previous quarter and by 44% YoY

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 9% greater than its total liabilities
AMRX's quick ratio is up by 14% from the previous quarter and by 7% YoY
The company's current ratio rose by 2.7% YoY and by 2.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.